Analysts have been eager to weigh in on the Healthcare sector with new ratings on Adaptimmune Therapeutics (ADAP – Research Report) and Tandem Diabetes Care (TNDM – Research Report).
Adaptimmune Therapeutics (ADAP)
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Adaptimmune Therapeutics on December 6 and set a price target of $9.00. The company’s shares closed last Friday at $0.54, close to its 52-week low of $0.42.
According to TipRanks.com, Goldstein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Adaptimmune Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.33.
See the top stocks recommended by analysts >>
Tandem Diabetes Care (TNDM)
Leerink Partners analyst Mike Kratky maintained a Hold rating on Tandem Diabetes Care on December 6. The company’s shares closed last Friday at $24.01.
According to TipRanks.com, Kratky is a 3-star analyst with an average return of
Tandem Diabetes Care has an analyst consensus of Moderate Buy, with a price target consensus of $29.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ADAP:
